P-BCMA-ALLO1 CAR-T cells not checked

Poseida Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Allogeneic BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy”In the company’s words, NCT04960579 on ClinicalTrials.gov
Tested for
Multiple Myeloma
Main trialPhase 1
“Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).”In the company’s words, NCT04960579 on ClinicalTrials.gov

Other drugs for Multiple Myeloma

All 133 drugs for Multiple Myeloma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Mar 2029 P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow P-BCMA-ALLO1 CAR-T cells

Following is part of Solo: you see every change to P-BCMA-ALLO1 CAR-T cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in